Vigil Neuroscience

VIGL

市值 US$3.76億

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Vigil Neuroscience, Inc. (NasdaqGS: VIGL) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Vigil will receive $8.00 in cash for each share of Vigil that they own as well as a non-tradeable contingent value right entitling the holder to potentially receive an ad.

The mean of analysts' price targets for Vigil Neuroscience (VIGL) points to a 26.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

NEW YORK , June 9, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: TuHURA Biosciences, Inc. (NASDAQ: HURA)'s  merger with Kineta, Inc. If you are a TuHURA shareholder, click here to learn more about your legal rights and options . Vigil Neuroscience, Inc. (NASDAQ: VIGL)'s  sale to Sanofi.

The average of price targets set by Wall Street analysts indicates a potential upside of 26.9% in Vigil Neuroscience (VIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

PHILADELPHIA , June 4, 2025 /PRNewswire/ -- The law firm of Kaskela Law LLC announces that it is investigating the fairness of the recently announced proposed buyout of Vigil Neuroscience, Inc. ("Vigil") (NASDAQ: VIGL) shareholders. Click here for additional information about your legal rights and options: https://kaskelalaw.com/case/vigil-neuroscience/ On May 21, 2025, Vigil announced that it had agreed to be acquired by Sanofi at an upfront price of $8.00 per share in cash plus a non-transferable contingent value right (CVR) worth an additional $2.00 in cash upon the achievement of certain milestones.

WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP).

After reaching an important support level, Vigil Neuroscience, Inc. (VIGL) could be a good stock pick from a technical perspective. VIGL recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

NYC, May 24, 2025 (GLOBE NEWSWIRE) -- NEW YORK, May 24, 2025 / GlobeNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Vigil Neuroscience, Inc. (NASDAQ:  VIGL ), relating to the proposed merger with French company, Sanofi. Under the terms of the agreement, Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis.                Click here for more  https://monteverdelaw.com/case/vigil-neuroscience-inc-vigl/. It is free and there is no cost or obligation to you.

The consensus price target hints at an 86.7% upside potential for Vigil Neuroscience (VIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Vigil Neuroscience, Inc. (NasdaqGS: VIGL) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Vigil will receive $8.00 in cash for each share of Vigil that they own as well as a non-tradeable contingent value right entitling the holder to potentially receive an ad.